Delft and Zurich-based Cradle, a platform that helps scientists design and program proteins, announced on Thursday that it has come out of stealth and raised €5.5M in a Seed round of funding.
The round was co-led by Index Ventures and Kindred Capital with participation from angel investors, including Feike Sijbesma, Honorary Chairman and former CEO of Royal DSM, and Emily Leproust, founder of Twist Bioscience.
The Dutch-Swiss company says it will use the funds to accelerate product development, build its offering in programmable biology, scale its team, and support the onboarding of more design partners.
What does Cradle solve?
Synthetic biology is a multidisciplinary area of research that involves adapting the genes of bacteria and fungi to create ‘cell factories’ that use programmable proteins to produce various everyday products.